Global NGS-Based Monitoring and Diagnostic Test Market Growth (Status and Outlook) 2024-2030

Global NGS-Based Monitoring and Diagnostic Test Market Growth (Status and Outlook) 2024-2030

According to this study, the global NGS-Based Monitoring and Diagnostic Test market size will reach US$ million by 2030.

NGS-Based Monitoring and Diagnostic Test is based on the NGS, aiming for the monitoring and diagnostic test. Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionised genomic research. Using NGS an entire human genome can be sequenced within a single day.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report presents a comprehensive overview, market shares, and growth opportunities of NGS-Based Monitoring and Diagnostic Test market by product type, application, key players and key regions and countries.

Segmentation by product type:
Commercial Assays/Tests
Laboratory Developed Tests
Direct to Consumer Test
Pre-Commercial Tests

Segmentation by Application:
Out-Patient Clinics/General Practitioners
Diagnostic Centers
Hospitals
Others

This report also splits the market by region:
United States
China
Europe
Other regions:
Japan
South Korea
Southeast Asia
Rest of world

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Agilent Technologies, Inc.
Ancestry.com LLC
ArcherDX, Inc.
Beijing Genomics Institute (BGI)
Cancer Genetics, Inc.
CENTOGENE AG
F. Hoffmann-La Roche Ltd
GenePath Dx
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
QIAGEN N.V.
Quest Diagnostics Incorporated
Siemens Healthineers, Inc.
Thermo Fisher Scientific Inc.
HTG Molecular Diagnostics, Inc.
Vela Diagnostics Pte. Ltd.

Please note: The report will take approximately 2 business days to prepare and deliver.